Insmed Incorporated
Clinical trials sponsored by Insmed Incorporated, explained in plain language.
-
New daily inhaler could help PAH patients walk farther
Disease control Not yet recruitingThis study tests a once-daily inhaled powder (TPIP) to see if it helps people with pulmonary arterial hypertension (PAH) walk farther. About 344 adults with PAH will receive either TPIP or a placebo for 24 weeks. The main goal is to measure changes in a 6-minute walk test.
Phase: PHASE3 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated May 26, 2026 11:34 UTC
-
New hope for lung disease patients: inhaled drug shows promise in long-term safety trial
Disease control Not yet recruitingThis study looks at the long-term safety of an inhaled medication called treprostinil palmitil inhalation powder (TPIP) for people with pulmonary hypertension caused by interstitial lung disease. About 344 adults who finished a previous study will take the drug and be monitored f…
Phase: PHASE3 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated May 22, 2026 14:01 UTC